Keytruda strength fuels earnings beat for Merck (MRK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Merck (MRK) PT Raised to $127 at Morgan Stanley
January 30, 2024 10:52 AM ESTMorgan Stanley analyst Terrance Flynn raised the price target on Merck (NYSE: MRK) to $127.00 (from $116.00) while maintaining a Equalweight rating.... More
